Verve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Recommendation of "Buy" by Analysts

Shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) have received a consensus rating of "Buy" from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have covered the stock in the last year is $25.75.

Several analysts recently commented on the stock. Canaccord Genuity Group raised their price target on shares of Verve Therapeutics from $32.00 to $39.00 and gave the company a "buy" rating in a research report on Tuesday, April 15th. Guggenheim raised their price target on shares of Verve Therapeutics from $18.00 to $24.00 and gave the stock a "buy" rating in a research note on Tuesday, April 15th. William Blair reaffirmed an "outperform" rating on shares of Verve Therapeutics in a research note on Friday, February 21st. HC Wainwright boosted their price objective on shares of Verve Therapeutics from $15.00 to $25.00 and gave the company a "buy" rating in a report on Monday, April 14th. Finally, Cantor Fitzgerald upgraded shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a report on Tuesday, April 15th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Verve Therapeutics by 6.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 115,041 shares of the company's stock valued at $557,000 after purchasing an additional 6,595 shares during the period. Stifel Financial Corp grew its position in shares of Verve Therapeutics by 14.7% in the third quarter. Stifel Financial Corp now owns 131,406 shares of the company's stock valued at $636,000 after purchasing an additional 16,842 shares during the last quarter. State Street Corp increased its position in Verve Therapeutics by 27.0% during the third quarter. State Street Corp now owns 4,253,217 shares of the company's stock worth $20,586,000 after acquiring an additional 903,809 shares during the period. Public Employees Retirement System of Ohio boosted its stake in Verve Therapeutics by 27.3% during the third quarter. Public Employees Retirement System of Ohio now owns 58,700 shares of the company's stock worth $284,000 after buying an additional 12,600 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of Verve Therapeutics by 139.8% during the third quarter. Barclays PLC now owns 222,919 shares of the company's stock valued at $1,079,000 after acquiring an additional 129,944 shares during the period. Institutional investors own 97.11% of the company's stock.

Verve Therapeutics Price Performance

Shares of NASDAQ VERV traded up $0.21 during mid-day trading on Friday, hitting $5.68. 1,677,522 shares of the company's stock traded hands, compared to its average volume of 1,752,622. The company has a market capitalization of $504.36 million, a P/E ratio of -2.31 and a beta of 1.86. The company's 50-day moving average is $5.45 and its two-hundred day moving average is $5.92. Verve Therapeutics has a 1 year low of $2.86 and a 1 year high of $9.31.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share for the quarter, beating analysts' consensus estimates of ($0.72) by $0.14. The business had revenue of $13.08 million during the quarter, compared to analyst estimates of $3.94 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. Equities analysts anticipate that Verve Therapeutics will post -2.49 EPS for the current fiscal year.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.